Khaled, Najib Ben ; Seidensticker, Max ; Ricke, Jens ; Mayerle, Julia ; Oehrle, Bettina ; Rössler, Daniel ; Teupser, Daniel ; Ehmer, Ursula ; Bitzer, Michael 
; Waldschmidt, Dirk ; Fuchs, Martin ; Reuken, Philipp A ; Lange, Christian M ; Wege, Henning ; Kandulski, Arne ; Dechêne, Alexander ; Venerito, Marino ; Berres, Marie-Luise ; Luedde, Tom ; Kubisch, Ilja ; Reiter, Florian P ; De Toni, Enrico N
; Waldschmidt, Dirk ; Fuchs, Martin ; Reuken, Philipp A ; Lange, Christian M ; Wege, Henning ; Kandulski, Arne ; Dechêne, Alexander ; Venerito, Marino ; Berres, Marie-Luise ; Luedde, Tom ; Kubisch, Ilja ; Reiter, Florian P ; De Toni, Enrico N 
Zusammenfassung
The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in more than 80 countries. The efficacy and tolerability of this regimen suggest that the use of atezolizumab bevacizumab could be extended to the treatment of ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric